Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: A Gynecologic Oncology Group study Journal Article

Authors: Maxwell, G. L.; Tian, C.; Risinger, J.; Brown, C. L.; Rose, G. S.; Thigpen, J. T.; Fleming, G. F.; Gallion, H. H.; Brewster, W. R.; Mackey, D.
Article Title: Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: A Gynecologic Oncology Group study
Abstract: BACKGROUND. Previous studies have reported shorter survival of black women compared with white women who had advanced/recurrent endometrial cancer. It has been suggested that this may reflect racially based differences in treatment. METHODS. The authors retrospectively reviewed data from 169 black women and 982 white women with International Federation of Gynecologic Oncology (FIGO) Stage III, Stage IV, or recurrent endometrial carcinoma who were participants in 1 of 4 Gynecologic Oncology Group randomized treatment trials of doxorubicin alone or combined with paclitaxel and/or cisplatin. Demographic, histologic, treatment, and outcome data were analyzed to estimate survival, and between-group comparisons were performed. RESULTS. The pooled data revealed that black women were more likely to have papillary serous histology (P < .001), Stage IV disease (P < .001), and higher tumor grade (P < .001) compared with white women, and survival was worse among black women than among white women (median survival, 10.6 months vs. 12.2 months, respectively; P < .001). A Cox proportional hazards regression analysis that was adjusted for performance status, disease stage, tumor histology, tumor grade, and treatment demonstrated worse survival for black women (hazards ratio, 1.26, 95% confidence interval, 1.06-1.51; P =.010). CONCLUSIONS. The data from a large group of women with advanced/recurrent endometrial cancer suggested that a racial disparity in survival persists, despite the finding that black women and white women received similar treatment. Although the causes of racial disparity in endometrial cancer remain to be elucidated, socioeconomic, biologic, and cultural factors should be investigated to identify the etiologic origins of this multifactorial healthcare problem.
Keywords: survival; adult; cancer survival; controlled study; aged; survival analysis; major clinical study; clinical trial; histopathology; review; cisplatin; doxorubicin; advanced cancer; paclitaxel; cancer staging; outcome assessment; recurrent cancer; follow-up studies; endometrial cancer; endometrium carcinoma; endometrial neoplasms; neoplasm staging; adenocarcinoma; controlled clinical trial; neoplasm recurrence, local; randomized controlled trial; antineoplastic combined chemotherapy protocols; retrospective study; confidence interval; proportional hazards model; randomized controlled trials; medical society; racial disparity; race difference; african americans; european continental ancestry group; socioeconomics; african american; cultural factor; international cooperation; international federation of gynecologic oncology
Journal Title: Cancer
Volume: 107
Issue: 9
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2006-11-01
Start Page: 2197
End Page: 2205
Language: English
DOI: 10.1002/cncr.22232
PUBMED: 17001661
PROVIDER: scopus
Notes: --- - "Cited By (since 1996): 23" - "Export Date: 4 June 2012" - "CODEN: CANCA" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Carol Brown
    150 Brown